South San Francisco, CA October 4, 2023 Press Release Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment RAINBOWFISH study met its primary endpoint with 80% of…
Tag: Evrysdi®
Genentech Update on Evrysdi for Childhood Severe Spinal Muscular Atrophy
South San Francisco, CA July 2, 2023 Press Release Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk Data from ongoing…
Genentech’s Evrysdi and Types 2 and 3 Spinal Muscular Atrophy Update
South San Francisco, CA March 20, 2023 Press Release New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Data…